Biotech Companies

720 companies | Drug discovery and development companies

#	COMPANY	THERAPEUTIC AREAS	STAGE
1.	1ST Biotherapeutics, Inc. Yongin, South Korea	Rare Diseases	Phase 1	VIEW
2.	3SBio Inc. Shenyang, China	Oncology Hematology Immunology	Phase 3	VIEW
3.	4 Animals AlsterScience GmbH Hamburg, Germany	Immunology Oncology Infectious Disease	Preclinical	VIEW
4.	4D Pharma plc Leeds, United Kingdom	Oncology Immunology Gastroenterology	Preclinical to Phase II (at time of administration)	VIEW
5.	AAVantgarde Bio Milan, Italy	Rare Diseases Ophthalmology	Phase 1/2	VIEW
6.	AC Immune SA Lausanne, Switzerland		Phase 2	VIEW
7.	ADARx Pharmaceuticals San Diego, USA	Neuroscience Immunology Oncology	Phase 3	VIEW
8.	ADMA Biologics, Inc. Ramsey, New Jersey, United States		Commercial + Preclinical	VIEW
9.	AGS Therapeutics Paris, France	Ophthalmology Immunology Infectious Disease+2	Preclinical	VIEW
10.	ALX Oncology South San Francisco, United States	Oncology	Phase 1 / Phase 2	VIEW
11.	ANSTO (Australian Nuclear Science and Technology Organisation) Sydney, Australia	Oncology Cardiovascular Neuroscience	Commercial	VIEW
12.	Aardvark Therapeutics San Diego, USA	Rare Diseases Metabolic	Phase 3	VIEW
13.	AbCellera Vancouver, Canada	Metabolic Immunology Oncology	Phase 2	VIEW
14.	Abbisko Therapeutics Shanghai, China	Oncology	Phase 3	VIEW
15.	Abcuro, Inc. Newton, Massachusetts, USA	Immunology Oncology Rare Diseases	Phase 2/3	VIEW
16.	Abdera Therapeutics South San Francisco, USA / Vancouver, Canada	Oncology	Phase 1	VIEW
17.	Abeona Therapeutics Inc. Cleveland, Ohio, USA	Rare Diseases Ophthalmology Dermatology	Commercial	VIEW
18.	Abivax Paris, France	Immunology Gastroenterology	Phase 3	VIEW
19.	Acadia Pharmaceuticals Inc. San Diego, USA	Neuroscience Rare Diseases	Commercial	VIEW
20.	Accent Therapeutics Lexington, Massachusetts, United States	Oncology	Phase 1/2	VIEW
21.	Acelot South San Francisco, California, USA	Metabolic Oncology	Preclinical	VIEW
22.	Acepodia Alameda, USA / Taipei, Taiwan	Oncology Immunology	Phase 1	VIEW
23.	Acerand Therapeutics Carmel, USA / Shanghai, China	Oncology Immunology	Phase 1/2	VIEW
24.	Actinogen Medical Sydney, Australia		Phase 2/3	VIEW
25.	AcuraStem Monrovia, California, USA		Preclinical	VIEW
26.	AdvantiGen Biosciences Madison, WI, United States	Oncology Immunology	Discovery	VIEW
27.	Aegros Macquarie Park, Australia	Infectious Disease Immunology	Clinical	VIEW
28.	Aerogen Pharma San Mateo, USA / Galway, Ireland	Respiratory	Phase 3	VIEW
29.	Affitech Copenhagen, Denmark (with R&D in Oslo, Norway and San Francisco, USA)	Oncology Immunology Infectious Disease	Clinical	VIEW
30.	AgeneBio Baltimore, MD, USA	Neuroscience	Phase 2	VIEW
31.	Agios Pharmaceuticals Cambridge, USA	Rare Diseases Hematology Metabolic	Commercial	VIEW
32.	Agomab Therapeutics Antwerp, Belgium	Gastroenterology Rare Diseases	Phase 2	VIEW
33.	AiCuris Anti-infective Cures AG Wuppertal, Germany	Infectious Disease	Phase 3	VIEW
34.	Aitia Somerville, Massachusetts, USA	Oncology Immunology	Discovery	VIEW
35.	Akebia Therapeutics Cambridge, USA	Rare Diseases	Commercial	VIEW
36.	Akeso, Inc. Guangdong, China	Oncology Immunology	Commercial	VIEW
37.	Akribes Biomedical Vienna, Austria	Dermatology	Preclinical	VIEW
38.	Alchemab Therapeutics Cambridge, United Kingdom	Oncology Immunology	Phase 1	VIEW
39.	Alderys Orsay, France		Discovery	VIEW
40.	AlgiPharma AS Sandvika, Norway	Respiratory Infectious Disease	Phase 2	VIEW
41.	Alkermes plc Dublin, Ireland	Neuroscience	Commercial	VIEW
42.	Alkeus Pharmaceuticals Cambridge, USA	Ophthalmology Rare Diseases	Phase 3	VIEW
43.	Allergy Therapeutics Worthing, United Kingdom		Phase 3 and Phase 1/2	VIEW
44.	Allotera Therapeutics St. Louis, USA	Oncology Hematology Immunology	Pivotal	VIEW
45.	Allotera Therapeutics (formerly Wugen, Inc.) St. Louis, USA	Oncology	Phase 2	VIEW
46.	Allygen Biosciences Shanghai, China	Oncology Immunology	Preclinical	VIEW
47.	Alnylam Pharmaceuticals Cambridge, USA	Infectious Disease	Commercial	VIEW
48.	AlphaGen Therapeutics Shanghai, China	Oncology	Preclinical	VIEW
49.	AltruBio, Inc. San Francisco, USA	Immunology	Phase 2	VIEW
50.	Alumis Inc. South San Francisco, USA	Immunology Dermatology Neuroscience+1	Phase 3	VIEW
51.	Alvotech Luxembourg, Luxembourg	Immunology Ophthalmology Oncology+1	Commercial	VIEW
52.	Amgen Thousand Oaks, California, United States	Oncology Immunology Metabolic+1	Discovery through Commercial	VIEW
53.	Amicus Therapeutics Princeton, New Jersey, USA	Rare Diseases Metabolic	Commercial	VIEW
54.	Ampersand Biomedicines Boston, MA, USA	Metabolic	Preclinical	VIEW
55.	Amylyx Pharmaceuticals Cambridge, USA	Rare Diseases	Phase 3	VIEW
56.	Anavex Life Sciences Corp. New York, United States	Oncology	Phase 2\|Phase 3	VIEW
57.	Angal Biotechnologies Ltd. Suzhou, China	Oncology Infectious Disease	Preclinical	VIEW
58.	Anocca AB Södertälje, Sweden	Oncology Immunology Infectious Disease	Phase 1	VIEW
59.	Antares Therapeutics Boston, USA	Oncology	Preclinical	VIEW
60.	Anwita Biosciences, Inc. San Carlos, USA	Oncology	Phase 1	VIEW
61.	Anyea Therapeutics Co., Ltd. Shanghai, China	Neuroscience	Discovery	VIEW
62.	Apateya Bordeaux, France	Neuroscience	Preclinical	VIEW
63.	Apeiron Therapeutics (GT Apeiron LLC) Burlingame, USA / Shanghai, China	Oncology	Phase 1	VIEW
64.	Apellis Pharmaceuticals, Inc. Waltham, Massachusetts, USA	Ophthalmology Rare Diseases Immunology	Commercial	VIEW
65.	Apogee Therapeutics, Inc. Waltham, USA	Dermatology Respiratory	Phase 2	VIEW
66.	Appili Therapeutics Inc. Halifax, Canada	Infectious Disease	Commercial	VIEW
67.	Aprogen Seongnam-si, South Korea	Oncology Immunology	Commercial	VIEW
68.	Aptose Biosciences Inc. Toronto, Canada	Oncology Hematology	Phase 2	VIEW
69.	Aquinas Companies, LLC (Fannin Innovation Studio) Houston, Texas, USA	Oncology Infectious Disease Cardiovascular+2	Phase 2	VIEW
70.	Araceli Biosciences Tigard, Oregon, United States		Seed	VIEW
71.	Aramis Biotechnologies Quebec City, Canada	Infectious Disease	Phase 1/2	VIEW
72.	Arcus Biosciences Hayward, United States	Oncology Immunology	Phase 3	VIEW
73.	Ardelyx Waltham, Massachusetts, USA	Gastroenterology	Commercial	VIEW
74.	Argo Biopharma Shanghai, China	Cardiovascular Metabolic Hematology+2	Phase 2	VIEW
75.	Ark Biosciences Shanghai, China	Respiratory Infectious Disease Neuroscience	Commercial	VIEW
76.	Arrivo BioVentures Morrisville, USA	Neuroscience Gastroenterology	Phase 2	VIEW
77.	Arrowhead Pharmaceuticals Pasadena, California, United States	Metabolic	Commercial \| Phase 3 \| Phase 2 \| Phase 1	VIEW
78.	Artica Therapeutics Leiden, Netherlands	Immunology	Preclinical	VIEW
79.	Artificial Axon Labs Cambridge, Massachusetts, USA	Neuroscience	Discovery	VIEW
80.	Artios Pharma Cambridge, United Kingdom	Oncology	Phase 2	VIEW
81.	Artiva Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
82.	Arvinas, Inc. New Haven, Connecticut, United States	Oncology Neuroscience	Phase 1-3	VIEW
83.	AryoGen Pharmed Karaj, Iran	Oncology Immunology Hematology	Commercial	VIEW
84.	Ascentage Pharma Suzhou, China	Oncology	Commercial	VIEW
85.	Asclepii Cleveland, USA		Commercial	VIEW
86.	AskGene Camarillo, California, United States	Oncology Immunology Ophthalmology	Phase 3	VIEW
87.	Asklepios BioPharmaceutical Research Triangle Park, North Carolina, USA	Metabolic	Phase 1\|Phase 2\|Preclinical	VIEW
88.	Aspect Biosystems Vancouver, Canada	Metabolic	Preclinical	VIEW
89.	AtaiBeckley (formerly ATAI Life Sciences) Berlin, Germany (original); U.S. redomiciliation completed December 30, 2025		Phase 2	VIEW
90.	Atara Biotherapeutics, Inc. Thousand Oaks, California, USA	Oncology Immunology	Clinical	VIEW
91.	Atea Pharmaceuticals Boston, Massachusetts, United States		Phase 3 (HCV), Phase 1 planned (HEV)	VIEW
92.	AudioCure Pharma GmbH Berlin, Germany		Phase 2	VIEW
93.	Aurefluidics Shanghai, China	Oncology Cell Therapy Gene Therapy	Commercial	VIEW
94.	Aurion Biotech Seattle, USA	Ophthalmology	Phase 3	VIEW
95.	AusperBio San Francisco, USA	Infectious Disease	Phase 2	VIEW
96.	Autobahn Therapeutics San Diego, USA	Neuroscience	Phase 2	VIEW
97.	Autolus Therapeutics London, United Kingdom	Oncology Immunology Rare Diseases	Commercial + Phase 1/2	VIEW
98.	Avenzo Therapeutics San Diego, USA	Oncology	Phase 2	VIEW
99.	Axalbion Lausanne, Switzerland	Respiratory Ophthalmology Neuroscience	Phase 2	VIEW
100.	BIKEN Foundation Suita, Japan	Infectious Disease	Commercial	VIEW
101.	BIOCAD Saint Petersburg, Russia	Oncology Immunology Infectious Disease	Commercial	VIEW
102.	BIOVIIIx Naples, Italy	Rare Diseases Hematology Oncology	Discovery	VIEW
103.	BPS Bioscience, Inc. San Diego, California, United States	Oncology Immunology Infectious Disease	Discovery	VIEW
104.	BRIM Biotechnology, Inc. Taipei, Taiwan	Ophthalmology Rare Diseases	Phase 3	VIEW
105.	Bavarian Nordic A/S Hellerup, Denmark	Infectious Disease Oncology Immunology	Commercial	VIEW
106.	BeBetter Med Inc. Guangzhou, China	Oncology	Commercial	VIEW
107.	Beeline Medicines Boston, USA	Immunology Dermatology	Phase 2	VIEW
108.	Beijing Sungen Biomedical Technology Co., Ltd. Beijing, China	Cardiovascular Oncology Infectious Disease	Phase 2	VIEW
109.	Belenos Biosciences New York, NY, USA	Immunology Respiratory Dermatology	Phase 1/2	VIEW
110.	Belief BioMed Shanghai, China	Rare Diseases Hematology Neuroscience+1	Commercial	VIEW
111.	BenevolentAI London, United Kingdom	Oncology Immunology Neuroscience+3	Phase 1\|Phase 2\|Preclinical	VIEW
112.	Benitec Biopharma Inc. Hayward, California, USA	Infectious Disease Oncology	Phase 1b/2a (BB-301), Preclinical (other programs)	VIEW
113.	Beren Therapeutics P.B.C. Thousand Oaks, USA	Rare Diseases	Phase 3	VIEW
114.	Berg Health Framingham, Massachusetts, USA	Oncology Neuroscience Rare Diseases	Phase 1/2	VIEW
115.	Bharat Biotech Hyderabad, India	Infectious Disease Oncology	Commercial	VIEW
116.	Bharat Serums and Vaccines Limited (BSV Group) Navi Mumbai, India		Commercial	VIEW
117.	Bicycle Therapeutics plc Cambridge, United Kingdom	Oncology	Phase 2	VIEW
118.	Bio Pharma Eco SL Spain		Discovery	VIEW
119.	Bio Usawa Inc. San Mateo, USA / Kigali, Rwanda	Oncology Infectious Disease Ophthalmology	Preclinical	VIEW
120.	BioCardia, Inc. Sunnyvale, California, USA	Cardiovascular Respiratory	Phase 3	VIEW
121.	BioChain Institute Inc. Newark, California, USA	Oncology Neuroscience Immunology+1	Commercial	VIEW
122.	BioInvent International AB Lund, Sweden	Oncology	Phase 2	VIEW
123.	BioLineRx Ltd. Modiin, Israel	Oncology Rare Diseases	Commercial	VIEW
124.	BioMarin Pharmaceutical Inc. San Rafael, USA	Hematology Metabolic Cardiovascular	Commercial	VIEW
125.	BioMed Valley Discoveries Kansas City, Missouri, USA	Oncology Immunology Rare Diseases+1	Clinical (Phase 1-2)	VIEW
126.	BioNTech Mainz, Germany	Oncology Immunology Infectious Disease	Phase 1-3	VIEW
127.	BioNTech SE Mainz, Germany	Oncology Infectious Disease Rare Diseases	Commercial	VIEW
128.	BioOra Limited Wellington, New Zealand	Oncology	Phase 2	VIEW
129.	Biocase Brasil Itajaí, Brazil		Preclinical	VIEW
130.	Biocytogen Pharmaceuticals (Beijing) Co., Ltd. Beijing, China	Oncology Immunology Metabolic+1	Phase 2	VIEW
131.	Biogen Cambridge, Massachusetts, USA		Phase 1-Phase 3; Commercial	VIEW
132.	Biohaven Ltd. New Haven, USA	Neuroscience Immunology Oncology+1	Phase 3	VIEW
133.	Biological E. Limited Hyderabad, India	Infectious Disease Gastroenterology	Commercial	VIEW
134.	BiomeBank Adelaide, Australia	Infectious Disease Gastroenterology Metabolic	Clinical	VIEW
135.	Biomea Fusion San Carlos, USA	Metabolic Oncology	Phase 2	VIEW
136.	Biomed Industries, Inc. San Jose, USA	Metabolic	Phase 2/3	VIEW
137.	Biovet AD Peshtera, Bulgaria		Commercial	VIEW
138.	Bioxodes Gosselies, Belgium	Neuroscience Immunology	Phase 2	VIEW
139.	BirchBioMed Inc. Vancouver, Canada	Dermatology Rare Diseases	Phase 2/3	VIEW
140.	BlossomHill Therapeutics San Diego, USA	Oncology Immunology	Phase 1	VIEW
141.	BlueRock Therapeutics Cambridge, USA	Neuroscience Cardiovascular Ophthalmology+1	Phase 3	VIEW
142.	Blueprint Medicines Cambridge, USA	Oncology Hematology Immunology+1	Commercial	VIEW
143.	Boostimmune Seoul, South Korea	Oncology Immunology	Preclinical	VIEW
144.	Bota Biosciences Hangzhou, China (International HQ in Lafayette, CA, USA)		Commercial	VIEW
145.	BrainXell, Inc. Madison, WI, USA	Neuroscience Rare Diseases	Preclinical	VIEW
146.	BridgeBio Oncology Therapeutics, Inc. South San Francisco, USA	Oncology	Phase 1	VIEW
147.	Bright Peak Therapeutics Allschwil, Switzerland	Oncology	Phase 1/2a	VIEW
148.	Brise Pharmaceuticals Shanghai, China		Phase 2	VIEW
149.	Broad Institute of MIT and Harvard Cambridge, USA	Oncology Rare Diseases Cardiovascular+1	Discovery	VIEW
150.	BunyaVax Lelystad, Netherlands	Infectious Disease Oncology	Phase 1	VIEW
151.	Byondis Nijmegen, Netherlands	Oncology	Phase 1	VIEW
152.	CAMP4 Therapeutics Cambridge, USA	Rare Diseases	Phase 1	VIEW
153.	CDR-Life Schlieren, Zurich, Switzerland	Oncology Immunology Ophthalmology	Phase 1	VIEW
154.	CEA (Commissariat à l'énergie atomique et aux énergies alternatives) Paris and Gif-sur-Yvette, France	Infectious Disease Oncology	Discovery	VIEW
155.	CEPI Oslo, Norway	Infectious Disease	Commercial	VIEW
156.	CG Oncology, Inc. Irvine, USA	Oncology	Phase 3	VIEW
157.	CHUV (Centre Hospitalier Universitaire Vaudois) Lausanne, Switzerland	Oncology Immunology Neuroscience+2	Phase 3	VIEW
158.	CPTx Planegg, Germany	Oncology Immunology Infectious Disease	Preclinical	VIEW
159.	CRUK Scotland Institute Glasgow, United Kingdom	Oncology	Discovery	VIEW
160.	CSL Limited Melbourne, Australia	Immunology Hematology Cardiovascular+3	Commercial	VIEW
161.	CSL Limited (CSL Behring is the largest division) Melbourne, Australia (corporate); King of Prussia, USA (CSL Behring)	Immunology Hematology Respiratory+1	Phase 1 through Commercial	VIEW
162.	CSL Seqirus Maidenhead, United Kingdom		Commercial	VIEW
163.	CURE5 Foundation New York, USA	Rare Diseases Neuroscience	Discovery	VIEW
164.	Cabaletta Bio, Inc. Philadelphia, USA	Immunology Neuroscience Dermatology	Phase 1/2	VIEW
165.	Caldera Therapeutics Cambridge, USA	Immunology Gastroenterology	Phase 1	VIEW
166.	Calico Life Sciences South San Francisco, United States	Oncology Neuroscience Immunology	Phase 2	VIEW
167.	Calidi Biotherapeutics San Diego, USA	Oncology	Phase 2	VIEW
168.	Calliditas Therapeutics Stockholm, Sweden	Rare Diseases	Commercial	VIEW
169.	Calluna Pharma Oslo, Norway	Immunology	Phase 2	VIEW
170.	Camelx Riyadh, Saudi Arabia		Discovery	VIEW
171.	Camurus AB Lund, Sweden	Neuroscience Rare Diseases Metabolic+1	Commercial	VIEW
172.	CanariaBio Inc. Seoul, South Korea	Oncology	Phase 3	VIEW
173.	Canopy Immuno-Therapeutics Megadim, Israel		Preclinical	VIEW
174.	Cantargia AB Lund, Sweden	Oncology Immunology	Phase 1 - Phase 2	VIEW
175.	Captor Therapeutics Wroclaw, Poland	Oncology Immunology	Preclinical	VIEW
176.	Capulus Therapeutics LLC San Francisco, United States	Oncology	Preclinical	VIEW
177.	Cardurion Pharmaceuticals Burlington, United States	Cardiovascular	Phase 2	VIEW
178.	Carrick Therapeutics Dublin, Ireland	Oncology	Phase 2	VIEW
179.	Cell-Tx Seoul, South Korea	Neuroscience Oncology Ophthalmology	Preclinical	VIEW
180.	Cellectar Biosciences, Inc. Florham Park, USA	Oncology Hematology	Phase 2	VIEW
181.	Cellectis Paris, France	Oncology Immunology Rare Diseases	Phase 2	VIEW
182.	Cellestia Biotech AG Basel, Switzerland	Oncology Immunology	Phase 2	VIEW
183.	Celltrion Incheon, South Korea	Immunology Oncology Ophthalmology+2	Commercial	VIEW
184.	Celon Pharma Łomianki, Poland	Neuroscience Oncology Immunology+1	Phase 3	VIEW
185.	Celularity Inc Florham Park, New Jersey, USA	Oncology	Phase 1/2 and Phase 2	VIEW
186.	Center for Genetic Engineering and Biotechnology (CIGB) Havana, Cuba	Oncology Metabolic Infectious Disease+1	Commercial	VIEW
187.	Center for Neuromusculoskeletal Restorative Medicine Limited Shatin, Hong Kong	Neuroscience Rare Diseases	Preclinical	VIEW
188.	Center of Molecular Immunology (CIM) Havana, Cuba	Oncology Immunology	Commercial	VIEW
189.	Centessa Pharmaceuticals Altrincham, United Kingdom	Neuroscience	Phase 2	VIEW
190.	Centrexion Therapeutics Boston, Massachusetts, United States	Immunology	Phase 1-3	VIEW
191.	Cerevel Therapeutics Cambridge, Massachusetts, USA		Phase 1-3	VIEW
192.	Chan Zuckerberg Biohub Network San Francisco, USA	Infectious Disease Rare Diseases Immunology	Discovery	VIEW
193.	Changchun GeneScience Pharmaceutical Co., Ltd. Changchun, China	Metabolic Oncology Immunology+1	Clinical	VIEW
194.	Chongqing PegBio Biotechnology Co., Ltd. Chongqing, China	Gastroenterology Hematology Oncology	Phase 3	VIEW
195.	Choose Life Biotech SA Bellinzona, Switzerland	Immunology Infectious Disease Oncology	Preclinical	VIEW
196.	ChuanXin Biomedicine Suzhou, China	Infectious Disease Oncology	Phase 1	VIEW
197.	Circio Holding ASA Lysaker, Norway	Oncology Immunology Gene Therapy	Phase 1/2	VIEW
198.	City Therapeutics Cambridge, United States	Hematology Ophthalmology Rare Diseases	Phase 1 and preclinical	VIEW
199.	Clasp Therapeutics Rockville, Maryland, USA	Oncology	Phase 1	VIEW
200.	ClearB Therapeutics, Inc. Concord, Massachusetts, USA	Infectious Disease	Phase 1	VIEW
201.	Clinuvel Pharmaceuticals Melbourne, Australia	Rare Diseases Dermatology Neuroscience	Commercial	VIEW
202.	Coave Therapeutics Paris, France	Ophthalmology Neuroscience Rare Diseases	Preclinical	VIEW
203.	Codexis, Inc. Redwood City, California, USA	Rare Diseases Metabolic	Commercial	VIEW
204.	Coherus BioSciences, Inc. Redwood City, USA	Oncology	Commercial	VIEW
205.	Comanche Biopharma Corp. Concord, USA		Phase 1	VIEW
206.	Complement Therapeutics United Kingdom (University of Manchester spinout, with facilities in UK and Germany)	Ophthalmology	Phase I/II	VIEW
207.	Constructor Group Schaffhausen, Switzerland	Oncology Infectious Disease Neuroscience	Preclinical	VIEW
208.	Cook MyoSite, Inc. Pittsburgh, USA	Gastroenterology	Phase 3	VIEW
209.	Corbus Pharmaceuticals Holdings, Inc. Norwood, Massachusetts, USA	Oncology Metabolic	Phase 3	VIEW
210.	Corline Biomedical AB Uppsala, Sweden	Metabolic Cardiovascular Neuroscience	Phase 2	VIEW
211.	Cosmica Biosciences San Francisco, USA		Discovery	VIEW
212.	Coya Therapeutics, Inc. Houston, USA	Immunology	Phase 2	VIEW
213.	Createrna Science and Technology Wuhan, China	Cardiovascular Respiratory Immunology	Phase 2	VIEW
214.	Crescent Biopharma, Inc. Waltham, USA	Oncology	Phase 1/2	VIEW
215.	Cugene Inc. Waltham, USA	Oncology Immunology	Phase 1	VIEW
216.	Cullinan Therapeutics Cambridge, USA	Oncology Immunology	Phase 3	VIEW
217.	CuraTeQ Biologics Hyderabad, India	Oncology Immunology Metabolic	Commercial	VIEW
218.	CuraVac Rixensart, Belgium	Immunology	Phase 1B (completed) \| Phase 2 (in preparation)	VIEW
219.	Curadev Pharma Pvt Ltd Noida, India	Oncology Immunology Metabolic	Phase 1	VIEW
220.	Curasight Copenhagen, Denmark	Oncology	Phase 1-2 Clinical	VIEW
221.	Curative Biotechnology Inc Boca Raton, Florida, USA	Infectious Disease	Pre-Clinical\|IND-Enabling Studies	VIEW
222.	CureVac Tübingen, Germany	Oncology Infectious Disease Rare Diseases	Phase 2	VIEW
223.	Curis, Inc. Lexington, USA	Oncology	Phase 1/2	VIEW
224.	Curocell Inc. Daejeon, South Korea	Oncology Hematology	Commercial	VIEW
225.	Cytiva Marlborough, Massachusetts, USA	Oncology Immunology Rare Diseases+1	Commercial	VIEW
226.	CytoAgents Pittsburgh, USA	Oncology Immunology Infectious Disease+1	Phase 2	VIEW
227.	CytoDyn Inc Vancouver, Washington	Oncology Immunology	Phase 2 clinical	VIEW
228.	CytoHub Inc. San Diego, USA	Cardiovascular	Preclinical	VIEW
229.	CytoImmune Therapeutics Duarte, USA	Oncology Hematology Immunology	Phase 1	VIEW
230.	CytoSen Therapeutics Orlando (Winter Springs), Florida, USA	Oncology Cell Therapy Immunology	Phase 2	VIEW
231.	CytoTools AG Heidelberg, Germany	Dermatology Cardiovascular Oncology	Phase 3	VIEW
232.	CytoVac Hørsholm, Denmark	Oncology	Phase 2	VIEW
233.	Cytochroma Edinburgh, United Kingdom	Cardiovascular Rare Diseases	Discovery	VIEW
234.	Cytocom, Inc. Fort Collins, Colorado, USA	Oncology Infectious Disease Hematology+1	Phase 2/Phase 3	VIEW
235.	Cytokinetics, Incorporated South San Francisco, USA	Cardiovascular	Commercial	VIEW
236.	CytomX Therapeutics, Inc. South San Francisco, California, United States	Oncology	Phase 1 (clinical), Preclinical (discovery collaborations)	VIEW
237.	Cytomos Edinburgh, United Kingdom	Cell Therapy Gene Therapy Oncology	Commercial	VIEW
238.	Cytonics Corporation Jupiter, Florida, USA	Immunology	Phase 2	VIEW
239.	Cytonus Therapeutics Carlsbad, California, United States	Oncology Immunology Infectious Disease+1	Phase 1	VIEW
240.	Cytorex Biosciences Weston, Florida, USA	Oncology Metabolic Infectious Disease	Preclinical	VIEW
241.	Cytovation Bergen, Norway	Oncology Rare Diseases	Phase I/II - Phase II	VIEW
242.	Cytovia Therapeutics Aventura, Florida, USA	Oncology Immunology	Phase 1/2	VIEW
243.	Cyxone Malmö, Sweden	Immunology Neuroscience	Phase 2	VIEW
244.	D&D Pharmatech Seongnam-si, South Korea		Phase 2	VIEW
245.	DBV Technologies Châtillon, France	Immunology	Phase 3	VIEW
246.	Danaher Corporation Washington, D.C., USA	Oncology Infectious Disease	N/A	VIEW
247.	Day One Biopharmaceuticals Brisbane, United States	Oncology Rare Diseases	Commercial	VIEW
248.	Debiopharm Lausanne, Switzerland	Oncology Rare Diseases	Phase 1, Phase 2, Phase 3	VIEW
249.	Denali Therapeutics Inc. South San Francisco, USA		Commercial	VIEW
250.	Dendreon Pharmaceuticals Seal Beach, USA	Oncology	Commercial	VIEW
251.	DesiCorp Inc. Louisville, USA		Preclinical	VIEW
252.	DevaCell, Inc. San Diego, USA	Oncology Infectious Disease Gene Therapy	Preclinical	VIEW
253.	Development Center for Biotechnology (DCB) Taipei, Taiwan	Oncology Immunology Infectious Disease	Preclinical	VIEW
254.	Differential Bio Munich, Germany		Commercial	VIEW
255.	Dignify Therapeutics Research Triangle Park, NC, USA	Neuroscience Gastroenterology	Clinical	VIEW
256.	Disc Medicine, Inc. Watertown, Massachusetts, USA	Hematology Rare Diseases	Phase 3	VIEW
257.	Dolor Therapeutics, Inc. Chicago, USA	Immunology	Preclinical	VIEW
258.	Dompé Farmaceutici Milan, Italy	Ophthalmology Rare Diseases Metabolic+2	Commercial	VIEW
259.	Drishti Discoveries Ltd Cambridge, United Kingdom	Rare Diseases	Preclinical	VIEW
260.	Drugs for Neglected Diseases initiative (DNDi) Geneva, Switzerland	Infectious Disease	Commercial	VIEW
261.	Duality Biologics Shanghai, China	Oncology Immunology	Phase 3	VIEW
262.	Dyne Therapeutics, Inc. Waltham, Massachusetts, USA		Phase 1/2, Phase 3	VIEW
263.	E-Flask Seongnam, South Korea	Neuroscience Oncology	Phase 1	VIEW
264.	Edge Therapeutics, Inc. Princeton, New Jersey, USA	Oncology Infectious Disease	Phase 3	VIEW
265.	Edgewise Therapeutics Boulder, USA		Phase 2	VIEW
266.	EdiLabs OÜ Harku, Estonia	Neuroscience Immunology	Discovery	VIEW
267.	Eledon Pharmaceuticals Irvine, USA	Immunology	Phase 2	VIEW
268.	Elevar Therapeutics Fort Lee, USA	Oncology	Phase 3	VIEW
269.	Eleven Therapeutics Cambridge, United Kingdom	Infectious Disease	Discovery	VIEW
270.	Elixiron Immunotherapeutics Taipei, Taiwan	Oncology Immunology	Phase 2	VIEW
271.	Ellipses Pharma London, United Kingdom	Oncology	Phase 1/2	VIEW
272.	Emergent BioSolutions Gaithersburg, Maryland, USA	Infectious Disease	Commercial	VIEW
273.	Enanta Pharmaceuticals, Inc. Watertown, Massachusetts, USA	Immunology	Phase 1-2 clinical	VIEW
274.	Eneapharm Labège, France	Gastroenterology Rare Diseases	Clinical	VIEW
275.	Enlivex Therapeutics Ltd. Ness Ziona, Israel	Immunology Oncology Infectious Disease	Phase 2	VIEW
276.	Ensem Therapeutics Waltham, MA, USA	Oncology	Phase 1/2	VIEW
277.	Entact Bio Watertown, USA	Oncology Immunology Rare Diseases	Preclinical	VIEW
278.	Enveda Biosciences Boulder, USA	Immunology Metabolic Dermatology	Clinical	VIEW
279.	Enzo Biochem, Inc. Farmingdale, New York, USA	Oncology Infectious Disease	Discovery	VIEW
280.	Estetra SRL Liège, Belgium	Oncology	Commercial	VIEW
281.	EuBiologics Co., Ltd. Seoul, South Korea	Infectious Disease	Phase 3	VIEW
282.	Everest Medicines Shanghai, China	Immunology Oncology Cardiovascular+1	Commercial	VIEW
283.	Evopoint Biosciences Suzhou, China	Oncology Infectious Disease Immunology	Commercial (NDA Stage)	VIEW
284.	Evox Therapeutics Oxford, United Kingdom	Rare Diseases Oncology	Preclinical	VIEW
285.	Exelixis Alameda, USA	Oncology	Commercial	VIEW
286.	EyePoint Pharmaceuticals Watertown, Massachusetts, USA	Ophthalmology	Phase 3	VIEW
287.	FELIQS Corporation Fukuoka, Japan	Ophthalmology Rare Diseases	Phase 1	VIEW
288.	FNCT Biotech Seongnam-si, South Korea	Oncology Immunology	Preclinical	VIEW
289.	FORE Biotherapeutics Philadelphia, USA	Oncology	Phase 2	VIEW
290.	Faron Pharmaceuticals Turku, Finland	Oncology Hematology	Phase 2	VIEW
291.	Fate Therapeutics, Inc. San Diego, USA	Oncology	Phase 1	VIEW
292.	Feldan Therapeutics Québec City, Canada	Oncology Dermatology	Preclinical	VIEW
293.	Finnadvance Oulu, Finland	Ophthalmology Rare Diseases	Commercial	VIEW
294.	Fiocruz (Oswaldo Cruz Foundation) Rio de Janeiro, Brazil	Infectious Disease	Commercial	VIEW
295.	Fishfa Biogenics Rajkot, India	Immunology Infectious Disease Oncology+1	Commercial	VIEW
296.	Flare Therapeutics Cambridge, MA, USA	Oncology	Phase 1-1B	VIEW
297.	Floratek Pharma SA Belmont-sur-Lausanne, Switzerland	Oncology	Preclinical	VIEW
298.	FluGen, Inc. Madison, USA	Infectious Disease	Phase 2	VIEW
299.	Forma Therapeutics Inc Watertown, USA	Hematology Oncology Rare Diseases	Phase 3	VIEW
300.	Formation Bio New York, USA	Immunology Dermatology Neuroscience	Phase 3	VIEW
301.	Formycon AG Planegg-Martinsried, Germany	Ophthalmology Immunology	Commercial	VIEW
302.	Frontier Medicines South San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
303.	Fundação Butantan São Paulo, Brazil	Infectious Disease	Phase 2	VIEW
304.	Fusion Pharmaceuticals Inc. Hamilton, Ontario, Canada	Oncology	Phase 1\|Phase 2\|Phase 3	VIEW
305.	Future Health Biobank Nottingham, United Kingdom		-	VIEW
306.	GC Biopharma Corp. (formerly Green Cross Corporation) Yongin, Gyeonggi Province, South Korea	Hematology Neuroscience Respiratory+2	Multiple stages (Discovery through Commercial)	VIEW
307.	GENFIT Loos, France	Metabolic	Phase 2	VIEW
308.	GNT Pharma Yongin, South Korea	Neuroscience Respiratory	Phase 3	VIEW
309.	Galapagos NV Mechelen, Belgium	Immunology Oncology	Phase 2	VIEW
310.	Galenicap BV Brussels, Belgium	Oncology Neuroscience Infectious Disease	Phase 2	VIEW
311.	GenAns Biotech Beijing, China	Neuroscience Ophthalmology Oncology	Preclinical	VIEW
312.	GenLumina Leiden, Netherlands	Oncology	Preclinical	VIEW
313.	Gene Oasis Singapore, Singapore	Oncology Neuroscience Immunology+1	Clinical	VIEW
314.	GeneScience Pharmaceuticals Co., Ltd. (GenSci) Changchun, China	Metabolic Immunology Respiratory+1	Commercial	VIEW
315.	GeneTex, Inc. Irvine, USA	Oncology Immunology Neuroscience+1	-	VIEW
316.	Genentech South San Francisco, California, United States	Oncology Immunology Rare Diseases+3	Discovery through Commercial	VIEW
317.	Generare Paris, France	Oncology Immunology	Discovery	VIEW
318.	Genfarma Joint Stock Company Hanoi, Vietnam	Oncology Immunology Neuroscience+1	Commercial	VIEW
319.	Genmab Copenhagen, Denmark	Oncology Hematology Immunology	Commercial	VIEW
320.	Gensciences Nantong, China	Hematology	Phase 3	VIEW
321.	Gesynta Pharma AB Stockholm, Sweden		Phase 2	VIEW
322.	Google (Google DeepMind / Isomorphic Labs) London, United Kingdom	Oncology Immunology Cardiovascular	Preclinical	VIEW
323.	Gossamer Bio San Diego, United States		Phase 3 / NDA preparation	VIEW
324.	Granite Bio Basel, Switzerland	Immunology	Phase 1	VIEW
325.	Grit Biotechnology Shenzhen, China	Oncology Immunology	Phase 2	VIEW
326.	Guangzhou Cellprotek Pharmaceutical Guangzhou, China	Neuroscience Cardiovascular Immunology+1	Phase 3 (Planning)	VIEW
327.	HCW Biologics Inc. Miramar, Florida, USA	Oncology Immunology	Phase 2	VIEW
328.	HERVolution Therapeutics Copenhagen, Denmark	Oncology	Preclinical	VIEW
329.	HIPRA Amer, Spain		Commercial	VIEW
330.	HLB PEP Co., Ltd. Gwangju, South Korea	Oncology Rare Diseases Immunology	Preclinical	VIEW
331.	HUN-REN Veterinary Medical Research Institute (VMRI) Budapest, Hungary	Infectious Disease	Discovery	VIEW
332.	HUTCHMED Hong Kong	Oncology Immunology Dermatology	Discovery to Phase III	VIEW
333.	Halozyme Therapeutics San Diego, USA	Oncology Immunology Neuroscience+3	Commercial	VIEW
334.	Hansa Biopharma Lund, Sweden	Immunology Gene Therapy Oncology	Commercial	VIEW
335.	Harbour BioMed Shanghai, China	Oncology Immunology Ophthalmology	Phase 3	VIEW
336.	Healios K.K. Tokyo, Japan	Neuroscience Oncology Ophthalmology	Phase 3	VIEW
337.	Healis Therapeutics Cambridge, USA	Neuroscience	Phase 2/3	VIEW
338.	Heligenics Phoenix, Arizona, USA	Oncology Rare Diseases	Discovery	VIEW
339.	Hemerion Therapeutics Villeneuve d'Ascq, France	Oncology	Phase 1/2	VIEW
340.	HepaRegeniX GmbH Tübingen, Germany	Oncology Neuroscience	Phase 2	VIEW
341.	Heranova Lifesciences Burlington, MA, USA		Clinical	VIEW
342.	HighField Biopharmaceuticals Hangzhou, China	Oncology Metabolic	Phase 1	VIEW
343.	Holostem S.r.l. Modena, Italy	Ophthalmology Dermatology Rare Diseases	Commercial	VIEW
344.	Hone Bio Bristol, United Kingdom	Oncology Cardiovascular	Preclinical	VIEW
345.	Huahui Health Ltd. Beijing, China	Oncology	Commercial	VIEW
346.	Humatrix Medical Suzhou, China	Cardiovascular	Preclinical/Early Clinical	VIEW
347.	HyperMabs Inc. Montreal, Canada	Oncology Infectious Disease	Discovery	VIEW
348.	IDEAYA Biosciences South San Francisco, USA	Oncology	Phase 3	VIEW
349.	IMIDomics, Inc. San Rafael, USA	Immunology Dermatology	Discovery	VIEW
350.	IMTR Inc. Tokyo, Japan	Immunology Hematology Gastroenterology	Phase 1/2	VIEW
351.	IPS Biopharma AG Bern, Switzerland	Oncology Infectious Disease	Phase 2	VIEW
352.	Idorsia Allschwil, Switzerland	Neuroscience Cardiovascular Immunology+1	Commercial	VIEW
353.	Ignis Therapeutics Shanghai, China	Neuroscience	Phase 3	VIEW
354.	Immatics N.V. Tübingen, Germany	Oncology	Phase 2	VIEW
355.	Immorna Biotherapeutics Morrisville, USA	Oncology Infectious Disease Dermatology+1	Phase 2	VIEW
356.	Immune System Key Ltd. (ISK) Jerusalem, Israel	Oncology	Phase 2	VIEW
357.	Immuneel Therapeutics Bengaluru, India	Oncology Hematology Immunology	Commercial	VIEW
358.	Immunethep Cantanhede, Portugal	Infectious Disease Immunology	Preclinical	VIEW
359.	Immunis, Inc. Irvine, California, USA	Immunology	Phase 1/2	VIEW
360.	ImmunityBio, Inc. Culver City, California, USA	Oncology Infectious Disease	Commercial	VIEW
361.	Immunocore Abingdon, United Kingdom	Oncology Infectious Disease Immunology	Commercial	VIEW
362.	Immunome, Inc. Bothell, Washington, USA	Oncology	Phase 3	VIEW
363.	Immunomic Therapeutics, Inc. Rockville, Maryland, United States	Oncology Infectious Disease	Phase 1 - Phase 2	VIEW
364.	Immunophotonics Saint Louis, Missouri, USA	Oncology Immunology	Phase 2/3	VIEW
365.	Immunovant, Inc. Durham, North Carolina, USA	Immunology Neuroscience Metabolic+1	Phase 3	VIEW
366.	Impact Therapeutics, Inc. Shanghai, China	Oncology	Commercial	VIEW
367.	Incepta Vaccine Ltd. Dhaka, Bangladesh	Infectious Disease	Commercial	VIEW
368.	Indian Immunologicals Limited Hyderabad, India	Infectious Disease Immunology	Commercial	VIEW
369.	Industrial Technology Research Institute (ITRI) Hsinchu County, Taiwan		Discovery	VIEW
370.	Infinitopes Oxford, United Kingdom	Oncology	Phase 1/IIa	VIEW
371.	Inhibrx Biosciences, Inc. La Jolla, California, USA	Oncology	Phase 2/3	VIEW
372.	Initial Therapeutics South San Francisco, USA	Oncology Rare Diseases	Discovery	VIEW
373.	InnoMedica Bern, Switzerland	Oncology	Phase 2	VIEW
374.	Innovacell Tokyo, Japan	Gastroenterology	Phase 3	VIEW
375.	Innovative Cell Technologies, Inc. San Diego, United States		Commercial	VIEW
376.	Innovent Biologics, Inc. Suzhou, China	Oncology	Commercial	VIEW
377.	Insilico Medicine Boston, USA	Oncology Immunology Neuroscience	Phase 2	VIEW
378.	InsilicoX Co., Ltd. Seoul, South Korea		Discovery	VIEW
379.	Insmed Incorporated Bridgewater, New Jersey, USA	Immunology Rare Diseases	Commercial	VIEW
380.	Institute for Bioengineering of Catalonia (IBEC) Barcelona, Spain	Oncology Neuroscience Rare Diseases+2	Preclinical	VIEW
381.	Institute of Immunology (Imunološki zavod) Zagreb, Croatia	Infectious Disease Immunology	Discovery	VIEW
382.	Intellia Therapeutics Cambridge, USA	Rare Diseases Cardiovascular Neuroscience+2	Phase 3	VIEW
383.	Intelligene Taipei, Taiwan	Infectious Disease	Phase 1	VIEW
384.	International Centre of Insect Physiology and Ecology (ICIPE) Nairobi, Kenya	Infectious Disease	Discovery\|Preclinical\|Phase 2	VIEW
385.	International Livestock Research Institute (ILRI) Nairobi, Kenya	Infectious Disease	Commercial	VIEW
386.	Interventional AnalgesiX Inc. Durham, North Carolina, United States		Preclinical	VIEW
387.	Intrommune Therapeutics New York, USA	Immunology	Phase 1	VIEW
388.	Inventiva Pharma Daix, France	Oncology	Phase 3	VIEW
389.	Ionis Pharmaceuticals, Inc. Carlsbad, California, United States	Neuroscience Cardiovascular Immunology+1	Phase 1 through Commercial	VIEW
390.	Ionis Pharmaceuticals, Inc. Carlsbad, USA	Neuroscience Rare Diseases	Commercial	VIEW
391.	J-Pharma Co., Ltd. Tokyo, Japan	Oncology Neuroscience Immunology	Phase 3	VIEW
392.	JCR Pharmaceuticals Co., Ltd. Ashiya, Japan	Rare Diseases Neuroscience	Phase 3	VIEW
393.	Janux Therapeutics San Diego, California, USA	Oncology Immunology	Phase 1	VIEW
394.	Japan Institute for Health Security Shinjuku-ku, Tokyo, Japan	Infectious Disease Vaccines	Discovery	VIEW
395.	Jiayue Pharmaceutical Guangzhou, China	Oncology Immunology Infectious Disease	Phase 3	VIEW
396.	Josep Carreras Leukaemia Research Institute (IJC) Badalona, Spain		Discovery	VIEW
397.	Jubilant Therapeutics Bedminster, NJ, United States	Oncology Immunology	Phase I/II Clinical	VIEW
398.	Junshi Biosciences Shanghai, China	Oncology Immunology Metabolic+1	Commercial	VIEW
399.	KM Biologics Co., Ltd. Kumamoto, Japan	Infectious Disease Hematology Immunology	Commercial	VIEW
400.	Kailera Therapeutics Waltham, MA, USA	Metabolic	Phase 3	VIEW
401.	Kali Therapeutics, Inc. San Mateo, California, USA	Oncology	Phase 1	VIEW
402.	KaliVir Immunotherapeutics Pittsburgh, Pennsylvania, USA	Oncology Immunology	Phase 1/1b Clinical	VIEW
403.	Kardigan South San Francisco, USA		Phase 2/3	VIEW
404.	Karyon Bio Bengaluru, India (with US presence in Mountain View, California)		Discovery	VIEW
405.	Karyopharm Therapeutics Newton, Massachusetts, USA	Oncology Hematology	Commercial	VIEW
406.	Kashiv BioSciences Piscataway, New Jersey, USA	Oncology Immunology	Phase 3	VIEW
407.	Kedrion Biopharma Barga, Italy	Immunology Hematology Rare Diseases	Commercial	VIEW
408.	Kenai Therapeutics San Diego, USA	Neuroscience	Phase 1	VIEW
409.	Keros Therapeutics Lexington, Massachusetts, United States	Hematology Respiratory Cardiovascular	Phase 1-3	VIEW
410.	Keymed Biosciences Chengdu, China	Immunology Oncology	Commercial	VIEW
411.	Khartis Therapeutics, Inc. San Diego, USA	Immunology	Discovery	VIEW
412.	Kiniksa Pharmaceuticals London, United Kingdom	Cardiovascular Immunology Rare Diseases	Commercial	VIEW
413.	Kite Pharma Santa Monica, USA	Oncology	Commercial	VIEW
414.	Kodiak Sciences Inc. Palo Alto, USA	Ophthalmology	Phase 3	VIEW
415.	Kolon Group Gwacheon, South Korea	Neuroscience Oncology Dermatology	Phase 3	VIEW
416.	Korea Research Institute of Bioscience and Biotechnology Daejeon, South Korea	Oncology Infectious Disease	Discovery	VIEW
417.	Korro Bio, Inc. Cambridge, USA	Rare Diseases Neuroscience	Phase 1/2	VIEW
418.	KromaTiD, Inc. Longmont, USA	Oncology Rare Diseases Gene Therapy+1	Discovery	VIEW
419.	Krystal Biotech, Inc. Pittsburgh, USA	Dermatology Respiratory Oncology+1	Commercial	VIEW
420.	Kura Oncology Inc San Diego, California, USA	Oncology	Phase 1\|Phase 2\|Phase 3\|Approved	VIEW
421.	Kymera Therapeutics, Inc. Watertown, Massachusetts, USA	Immunology Oncology	Phase 2	VIEW
422.	LFB USA Framingham, USA	Immunology	Commercial	VIEW
423.	Lamark Biotech Ahmedabad, India	Oncology	Preclinical	VIEW
424.	Laurent Pharmaceuticals Montreal, Quebec, Canada		Phase 2/3	VIEW
425.	Legend Biotech Somerset, New Jersey, USA	Oncology Hematology Infectious Disease	Commercial	VIEW
426.	Legend Biotech Somerset, USA	Oncology Infectious Disease	Commercial	VIEW
427.	Lepu Biopharma Co., Ltd. Shanghai, China	Oncology	Commercial	VIEW
428.	LiBo Pharma Corp. New Taipei City, Taiwan	Oncology Hematology Immunology	Phase 2/Phase 3	VIEW
429.	Libio Technology Suzhou, China	Cardiovascular Metabolic	Phase 1	VIEW
430.	Lion TCR Singapore, Singapore	Oncology Infectious Disease	Phase 2	VIEW
431.	MAB Discovery GmbH Polling, Germany	Oncology Immunology	Preclinical	VIEW
432.	MEPSGEN Seoul, South Korea	Neuroscience Oncology Rare Diseases	Preclinical	VIEW
433.	Mahzi Therapeutics South San Francisco, USA	Rare Diseases	Phase 1/2	VIEW
434.	MannKind Corporation Westlake Village, California, USA	Metabolic	Commercial	VIEW
435.	Mariana Oncology (via Carroll Bio Advisory) Watertown, Massachusetts	Oncology	Phase 1	VIEW
436.	Marinomed Biotech AG Korneuburg, Austria	Immunology Ophthalmology	Phase 3	VIEW
437.	MediLink Therapeutics Suzhou, China	Oncology	Phase 2	VIEW
438.	MedinCell Montpellier, France		Commercial\|Phase 3\|Preclinical	VIEW
439.	Medytox Inc. Seoul, South Korea	Neuroscience Dermatology	Phase 3	VIEW
440.	Menarini Stemline New York, USA	Oncology Hematology Rare Diseases	Commercial	VIEW
441.	Mersana Therapeutics Cambridge, USA	Oncology Rare Diseases	Phase 1	VIEW
442.	Merus N.V. Utrecht, Netherlands	Oncology	Commercial (BLA Stage)	VIEW
443.	Mesa Green Pharma Frederick, USA	Neuroscience	Preclinical	VIEW
444.	Metagenomi Emeryville, USA	Hematology Cardiovascular Rare Diseases+1	Preclinical	VIEW
445.	Metagenomi Therapeutics, Inc. Emeryville, United States	Hematology Rare Diseases	Preclinical	VIEW
446.	MetrioPharm AG Zurich, Switzerland	Infectious Disease Rare Diseases Immunology	Phase 2	VIEW
447.	Micro CRISPR Vapi, India	Oncology Hematology Metabolic+1	Preclinical	VIEW
448.	Miltenyi Biotec Bergisch Gladbach, Germany	Oncology Immunology Hematology	Commercial	VIEW
449.	Minovia Therapeutics Tirat Carmel, Israel	Rare Diseases Hematology	Phase 2	VIEW
450.	Mirum Pharmaceuticals Foster City, USA	Rare Diseases	Commercial	VIEW
451.	Mobius Care Cleveland, USA		Discovery	VIEW
452.	Moderna Cambridge, USA	Infectious Disease Oncology Rare Diseases+2	Commercial	VIEW
453.	Mogam Institute for Biomedical Research Seoul, South Korea	Rare Diseases Infectious Disease Oncology+1	Discovery\|Preclinical	VIEW
454.	Monimoi Therapeutics Boston, USA	Oncology	Discovery	VIEW
455.	Monte Rosa Therapeutics Boston, USA	Oncology Immunology	Phase 1/2	VIEW
456.	Mucpharm Kogarah, Sydney, New South Wales 2217, Australia	Oncology Rare Diseases	Phase 2	VIEW
457.	MultiOmic Health London, United Kingdom	Metabolic	Discovery	VIEW
458.	Muna Therapeutics Frederiksberg, Denmark		Phase 1	VIEW
459.	Myrio Therapeutics Melbourne, Australia	Oncology	Discovery	VIEW
460.	N4 Pharma Chellaston, Derbyshire, United Kingdom	Oncology	Preclinical	VIEW
461.	NBE Therapeutics Basel, Switzerland	Oncology	Phase 1/2	VIEW
462.	NEUVOGEN, Inc. San Diego, USA	Oncology	Clinical	VIEW
463.	NKure Therapeutics Bengaluru, India	Oncology Infectious Disease	Preclinical	VIEW
464.	NMD Pharma A/S Aarhus, Denmark		Phase 2	VIEW
465.	Naiji Pharmaceutical Technology (Hangzhou) Co., Ltd. Hangzhou, China	Gene Therapy	Discovery	VIEW
466.	Nalu Bio San Francisco, USA		Preclinical	VIEW
467.	Nanjing Vazyme Biotech Co., Ltd. Nanjing, China	Infectious Disease Oncology Cardiovascular	Commercial	VIEW
468.	Nanocan Therapeutics Corporation Princeton, New Jersey (also noted as National Harbor, MD)	Oncology	Phase I/II	VIEW
469.	Nanogen Pharmaceutical Biotechnology JSC Ho Chi Minh City, Vietnam	Oncology Infectious Disease	Commercial	VIEW
470.	Nanophoria Milan, Italy	Cardiovascular Rare Diseases	Preclinical	VIEW
471.	Nanoscope Therapeutics Dallas, USA	Ophthalmology	Commercial	VIEW
472.	Navigator Medicines, Inc. Scotch Plains, New Jersey, USA	Immunology	Phase 2a (NAV-240), Phase 1 (NAV-242)	VIEW
473.	Nektar Therapeutics San Francisco, USA	Immunology	Phase 2	VIEW
474.	NervGen Pharma Corp. Vancouver, Canada	Neuroscience	Phase 3	VIEW
475.	Nerviano Medical Sciences Nerviano, Italy	Oncology Hematology	Phase 2	VIEW
476.	NeuCyte, Inc. San Carlos, United States	Neuroscience	Preclinical	VIEW
477.	Neuhyll Therapeutics, Inc. Newbury Park, USA		Phase 1	VIEW
478.	NeuroSense Therapeutics Herzliya, Israel		Phase 3	VIEW
479.	Neurocrine Biosciences San Diego, USA	Neuroscience Metabolic Rare Diseases	Commercial	VIEW
480.	Neurogene Inc. New York, NY	Neuroscience Rare Diseases	Phase 2	VIEW
481.	Neurophth Therapeutics Wuhan, China	Ophthalmology Rare Diseases	Phase 3	VIEW
482.	NextCure, Inc. Beltsville, Maryland, USA	Oncology Immunology	Phase 2	VIEW
483.	Nippi, Inc. Adachi-ku, Tokyo, Japan	Dermatology	Commercial	VIEW
484.	NorthStar Medical Radioisotopes, LLC Beloit, Wisconsin, USA	Oncology Cardiovascular	Commercial	VIEW
485.	Notogen Inc. Toronto, Canada		Preclinical	VIEW
486.	Nouveau Biosciences, Inc. Scarsdale, New York, USA	Oncology	Preclinical	VIEW
487.	NovaBridge Biosciences Rockville, Maryland, USA	Oncology Ophthalmology	Phase 2	VIEW
488.	NovaDigm Consulting Group Rockville, Maryland, USA	Infectious Disease Dermatology	Phase 2	VIEW
489.	Novavax, Inc. Gaithersburg, Maryland, USA	Infectious Disease	Commercial + Phase 3	VIEW
490.	Noveome Biotherapeutics Pittsburgh, Pennsylvania, USA	Ophthalmology Neuroscience Dermatology	Phase 1-2	VIEW
491.	Novonesis Lyngby, Denmark		Commercial	VIEW
492.	Numab Therapeutics AG Horgen, Switzerland	Oncology Immunology Dermatology	Clinical	VIEW
493.	NurExone Biologic Inc. Toronto, Canada / Haifa, Israel	Neuroscience	Preclinical	VIEW
494.	Nurix Therapeutics, Inc. San Francisco, USA	Oncology Immunology	Phase 1/2	VIEW
495.	Nuvalent, Inc. Cambridge, USA	Oncology	Phase 2	VIEW
496.	Nuvation Bio New York, United States	Oncology	Commercial	VIEW
497.	OSIVAX Lyon, France		Phase 2	VIEW
498.	OSR Health, Inc. Bellevue, USA	Oncology	Phase 2	VIEW
499.	Oban BioPharma Stamford, USA	Neuroscience	Preclinical	VIEW
500.	Obsidian Therapeutics Cambridge, Massachusetts, USA	Oncology	Phase 2	VIEW